Biosimulation Market Size to grow by USD 4742.9 million between 2024-2028
According to a research report “ Biosimulation Market” by End-user (Pharmaceuticals and biotechnology companies, Contract research and organizations, Others) Product (Software, Services) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 4742.9 million, at a CAGR of 18.52% during the forecast period. The global biosimulation market is experiencing significant growth due to substantial research investment in computational biology, specifically in modeling and simulation. Both public and private stakeholders are allocating resources towards this field to advance the development of therapies for intricate diseases. Regulatory bodies, such as the FDA, NIH, and EU, are providing research grants to companies and academic institutions to explore new possibilities in modeling and simulation. The FDA is also prioritizing new funding opportunities to enhance drug development safety through innovative methods, including modeling and simulation, streamlined trial designs, and basket and umbrella trials..
Browse market data tables, figures, and in-depth TOC on “Biosimulation Market” by End-user (Pharmaceuticals and biotechnology companies, Contract research and organizations, Others) Product (Software, Services) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By End-user, the Pharmaceuticals and biotechnology companies segment is projected to dominate the market size in 2024
The Biosimulation Market represents a significant growth opportunity for businesses seeking to optimize their biological processes through digital modeling and simulation. This market encompasses the development and deployment of software solutions that replicate the behavior of biological systems, enabling organizations to test hypotheses, optimize processes, and reduce costs associated with physical experimentation. By leveraging advanced technologies such as machine learning, AI, and high-performance computing, biosimulation solutions offer a cost-effective and efficient alternative to traditional laboratory methods. The global biosimulation market is expected to expand at a robust CAGR, driven by the increasing demand for personalized medicine, regulatory compliance, and research and development in various industries, including pharmaceuticals, agriculture, and energy.
By Product, Software segment is expected to hold the largest market size for the year 2024
The Biosimulation Market represents a significant growth opportunity for businesses seeking to optimize their biological processes through digital modeling and simulation. This market encompasses the development and deployment of software solutions that replicate the behavior of biological systems, enabling organizations to make data-driven decisions, improve product development, and enhance operational efficiency. Companies in pharmaceuticals, biotech, and academia are increasingly adopting biosimulation to reduce research and development costs, accelerate time-to-market, and mitigate risks.
North America is forecasted to hold the largest market size by region in 2024
The Biosimulation Market represents a significant growth opportunity for businesses seeking to optimize their biological processes through digital modeling and simulation. This market encompasses the development and deployment of software solutions that replicate the behavior of biological systems, enabling organizations to test hypotheses, design experiments, and improve product development. By leveraging biosimulation, companies can reduce costs, enhance efficiency, and mitigate risks associated with biological research and development.
The Biosimulation Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Biosimulation market is witnessing significant growth due to the increasing demand for human dosing measures in drug development, particularly for neurodegenerative conditions like Alzheimer's and Parkinson's diseases. Biosimulation, a computational modeling approach, enables the identification and optimization of drugs, including advanced and high potency ones, for these conditions. Regulatory authorities, such as the FDA and EMA, are increasingly recognizing the importance of biosimulation in drug development, especially in the context of pharmacogenetics and pharmacogenomics. Key players in the Biosimulation market include Certara, Rhenovia Pharma, and several others. The market is segmented into services and products. The services segment includes consulting and modeling services, while the product segment includes software solutions. The market is driven by the clinical urgency to develop drugs for neurodegenerative conditions, diabetes mellitus, bacterial infections, tuberculosis, cancer, drug resistance, and drug relapse cases. The market is expected to grow significantly in the coming years due to the increasing demand for personalized medicine and combination therapies.
Market Research Overview
The Biosimulation Market is witnessing significant growth due to the increasing demand for advanced drugs, high potency drugs, and the clinical urgency to develop treatments for chronic diseases, cancer, neurodegenerative conditions, and bacterial infections like tuberculosis. The market is segmented into ownership model, subscription model, and delivery model. The ownership model allows organizations to own the biosimulation software, while the subscription model provides access to the software on a pay-per-use or annual basis. The drug discovery and development process involves R&D decisions that rely on comparative effectiveness, clinical trial design, drug-drug interactions (DDI), human dosing measures, and drug identification. Biosimulation plays a crucial role in reducing the failure rate in drug development by providing virtual trials and predicting clinical outcomes. The market is further segmented into services and product segments. The services segment includes consulting and implementation services, while the product segment includes software solutions. Key players in the market include Certara, Rhenovia Pharma, and others. The market growth is driven by the digital health infrastructure, computational software expertise, and regulatory authorities' increasing acceptance of biosimulation in drug development. Machine learning (ML) and precision medicine are also expected to drive the market growth. Pharmacogenetics and pharmacogenomics are also gaining importance in drug development. The market is expected to grow significantly in the coming years due to the increasing demand for advanced drugs, drug development for cancer, and personalized medicine. The market is also expected to grow due to the rising number of drug resistance and drug relapse cases.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
